Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113360 | 0.84 | CDC25A (0.50) | CDC25ACDC25BPTPN1IDO1RAB9A | |
| SCHEMBL23234268 | 0.80 | ALDH1A1 (0.43) | RAB9AMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL6161470 | 0.79 | CES1 (0.39) | CDC25ACDC25BPTPN1IDO1PTGS2 | |
| SCHEMBL25176054 | 0.79 | PTPRC (0.44) | CDC25BHTR6RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4618562 | 0.78 | HTR6 (0.37) | HTR6MAPTALDH1A1HPGDCYP1A2 | |
| SCHEMBL7614983 | 0.78 | HTR6 (0.34) | HTR6 | |
| SCHEMBL14825946 | 0.76 | L3MBTL1 (0.42) | RAB9AMAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5393252 | 0.76 | MAPT (0.35) | CDC25ACDC25BPTPN1IDO1RAB9A | |
| SCHEMBL10028290 | 0.75 | PTPN1 (0.48) | CDC25ACDC25BPTPN1IDO1PTGS2 | |
| SCHEMBL7633782 | 0.75 | ALDH1A1 (0.41) | PTGS2MAPTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-0923589-B1 | 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6268444-B1 | TITANIUM, ZIRCONIUM OR HAFNIUM COMPOUNDS FOR POLYMERIZATION | DOW CHEMICAL COMPANY | 2001-07-31 | — | — | US | disclosed |
| US-6087292-A | Metallocene catalysts comprising indenyl ligands substituted with electronegative groups | TANGOR GMBH (DE) | 2000-07-11 | — | — | US | disclosed |
| EP-0923589-A1 | 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5763542-A | Process for the preparation of an olefin polymer using specific metallocenes | TARGOR GMBH (DE) | 1998-06-09 | — | — | US | disclosed |
| WO-1998006727-A1 | 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5504232-A | Process for the preparation of an olefin polymer using specific metallocenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-02 | — | — | US | disclosed |
| EP-0582195-A1 | Process for the preparation of polymers using specific metallocenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | CDC25A 548/4885CDC25B 990/4885PTPN1 222/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | CDC25A 381/4885CDC25B 1004/4885PTPN1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.